LS CancerDiag DiagMMR is a predictive diagnostic tool that enables preventive follow-up and counseling for affected mutation carriers who are at high risk for developing Lynch syndrome-related cancers. It is designed to detect MMR deficiency from a non-malignant tissue sample before tumors appear, making it a predictive instead of reactive test.

Unlike the current Lynch syndrome diagnosis, which relies heavily on tumor studies, DiagMMR provides conclusive and actionable results based on a minimally invasive tissue sample, without the knowledge and details of an inherited mutation. This removes the burden of uncertainty from both the patients and the treating medical professionals.

The quantitative DiagMMR method offers several benefits compared to the current diagnostic tools. It is a unique functional test that can replace the current large array of tests, and delivers results that are easy to interpret and actionable. This innovation supports cancer prevention, improves outcomes, and saves healthcare costs on a global scale.

LS CancerDiag DiagMMR represents a significant advancement in the field of Lynch syndrome diagnosis. Its predictive capabilities and unique functional test make it a valuable tool for healthcare professionals in managing patients at high risk of developing Lynch syndrome-related cancers.

Facebook Page of the Product

Twitter Page of the Product

linkedin Page of the Product

Website of the Product